Harvoni

With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

Orphan Drugs Among 2015's Top 10 Best-Selling Medications

Gilead Defends Hepatitis C Treatments On Reports Of Side Effects

Orphan Drugs Among 2015's Top 10 Best-Selling Medications

Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price

Gilead Sciences Price Target Trimmed Following A Sobering Q3

Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price

Gilead Sciences Price Target Trimmed Following A Sobering Q3

Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings

Gilead Vs. Merck: What To Know

Harvoni Recent News

Will Merck Encroach On Gilead's Harvoni Territory?

Gilead Trounces Hep C Estimates; Harvoni International Footprint Nearly Equals U.S.

Massachusetts Attorney General To Gilead Sciences: Cost Of Harvoni & Sovaldi Drugs 'May Constitute An Unfair Trade Practice In Violation Of Massachusetts Law'

Gilead Sciences Tumbles; Unconfirmed Reports Of Drug Pricing Changes In Japan

High Drug Prices Put Gilead Under Fire From Senate Committee

Gilead Sciences: Here's What A Bull And A Bear Are Saying

Keep An Eye On These 8 After-Hours Movers

Gilead Still A 'Buy' After Harvoni Approval In Japan, Maxim Proclaims

Gilead Soothes Price War Worry With Q1 Results

Is Gilead Sciences About To Buy Vertex For $45 Billion?

What's Wall Street Been Saying About Gilead Lately?

This Data Offers Insight Into Gilead Sales

Gilead Shares Tumble On Drug Warning; Baird Says Buy

A Look At 3 Biotech Stocks With Upside Potential

UPDATE: Barclays Initiates Coverage On Gilead Sciences, 'Should Remain Ahead Of Its Peers'